Tenderwize
Wróć do wyszukiwania

Open-house biologics rebate agreement for Epoetin beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 523 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-39 - Epoetin beta

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice contains two different end-time references: structured data gives 2028-01-30 22:59:59 UTC, while the XML not...

Participation is limited to pharmaceutical undertakings meeting the AMG and authorisation conditions for the specific p...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Supply-related pharmaceutical rebate agreement for Epoetin beta.
  • Open-house arrangement with uniform contractual conditions for all eligible participants.
Pokaż pełne podsumowanie

Open-house pharmaceutical supply arrangement for Epoetin beta in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical undertaking may join during the contract period, subject to the stated legal and self-declaration requirements. No contract value is provided. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents are only available electronically. The notice is in German and the extracted TED XML notice was analyzed, but no separate procurement document text was provided.

Ryzyka

The notice contains two different end-time references: structured data gives 2028-01-30 22:59:59 UTC, while the XML not...

Participation is limited to pharmaceutical undertakings meeting the AMG and authorisation conditions for the specific p...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-house biologics rebate agreement for Epoetin beta

Open-house contract for pharmaceutical rebate agreements under Section 130c(1) SGB V for the active substance Epoetin beta. The lot covers nationwide performance in Germany and is described as an open-house procedure with uniform conditions, no individual negotiations, and no exclusivity. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jan 2026 - Jan 2028

Kategoria

Pharmaceutical products

Termin

Deadline Jan 30, 2028

Szczegóły zamówienia

Data publikacji
03 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
803675-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3